Navigation Links
Interleukin Genetics, Inc. Reports Third Quarter 2007 Financial Results
Date:11/7/2007

721,090 937,770

Cost of consumer

products sold 995,769 675,101 2,882,072 675,101

Research and

development 785,942 721,731 2,246,340 2,382,390

Selling, general and

administrative 1,163,531 1,196,263 4,821,032 2,702,517

Amortization of

intangibles 413,209 145,322 1,236,074 193,830

Total operating

costs and

expenses 3,570,404 3,070,253 11,906,608 6,891,608

Loss from operations (1,009,119) (1,735,322) (4,517,578) (3,979,763)

Total other income and

expense, net (68,540) (98,327) (188,680) (366,546)

Net loss before income

taxes (1,077,659) (1,833,649) (4,706,258) (4,346,309)

Provision for income

taxes (4,000) - (12,000) -

Net loss $(1,081,659) $(1,833,649) $(4,718,258) $(4,346,309)

Net loss per basic and

diluted common share $(0.04) $(0.07) $(0.17) $(0.18)

Weighted average

common shares

outstanding 27,637,303 25,702,739 27,576,940 24,653,698


'/>"/>
SOURCE Interleukin Genetics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Interleukin Genetics Announces Management and Board Appointments
2. Interleukin Genetics President and Chief Scientific Officer to Present at Immunotoxicology V Conference
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. QMed, Inc. Reports July Medicare SNP Enrollments
5. Phlo Affiliate Reports Expanded Coverage to Oregon Border
6. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
7. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
8. Carrington Reports Second Quarter 2007 Results
9. Avitar Reports Third Quarter Financial Results for Fiscal 2007
10. Response Genetics Reports Second Quarter 2007 Financial Results
11. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... British Columbia and MENLO PARK, ... Pharmaceuticals, Inc. (OTCQX: DMPI) (DelMar and the Company), ... cancer therapies in new orphan drug indications, today announced ... been added as a clinical trial site for the ... with refractory glioblastoma multiforme (GBM), the most common and ...
(Date:4/16/2015)... 16, 2015  Northwest Biotherapeutics, Inc. (NASDAQ: ... non-toxic DCVax® personalized immune therapies for cancer, announced ... Loncar Cancer Immunotherapy Index (LCINDX), a professional index ... immunotherapy field within the biotechnology space.  ... 25 companies" in the immunotherapy space, including 6 ...
(Date:4/16/2015)... (PRWEB) April 16, 2015 Modality ... management systems for highly regulated industries, is pleased ... name a monthly columnist for Cold Chain IQ ... http://www.coldchainiq.com ). His column titled, Global Cold Chain ... information for today’s life sciences, pharmaceutical and healthcare ...
(Date:4/15/2015)... April 16, 2015 Immunocore ... drugs to treat cancer and other diseases, and ... of AstraZeneca, today announced that they have entered ... terms of the agreement, Immunocore will conduct a ... inhibitors MEDI4736 (anti-PD-L1) and/or tremelimumab (anti-CTLA-4) with IMCgp100, ...
Breaking Biology Technology:DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 2DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 3DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 4DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 5NW Bio Included In New Index Of The "Top 25 Cancer Immunotherapy Companies" 2NW Bio Included In New Index Of The "Top 25 Cancer Immunotherapy Companies" 3Modality Solutions Gary Hutchinson Named Columnist for Cold Chain IQ 2Modality Solutions Gary Hutchinson Named Columnist for Cold Chain IQ 3Immunocore and MedImmune Announce New Collaboration to Conduct Immuno-oncology Combination Trails in Melanoma 2Immunocore and MedImmune Announce New Collaboration to Conduct Immuno-oncology Combination Trails in Melanoma 3Immunocore and MedImmune Announce New Collaboration to Conduct Immuno-oncology Combination Trails in Melanoma 4Immunocore and MedImmune Announce New Collaboration to Conduct Immuno-oncology Combination Trails in Melanoma 5Immunocore and MedImmune Announce New Collaboration to Conduct Immuno-oncology Combination Trails in Melanoma 6
... by Stent Manufacturers Expected to ... - Witness Live Case Examples of Advanced Practices by Leading, Interventionalists, Broadcast from ... the Role of IVUS in Improving Stent, Results. - See How Many of the ... ...
... 22 Agendia BV, a,world leader in the rapidly ... Chief Research Officer Laura van ,t Veer has,received a ... Ribbon Breast Cancer Research Foundation. The Pink Ribbon ... 151 international breast cancer researchers with a total value ...
... CAMBRIDGE, Mass., Oct. 22 Genzyme Corp.,(Nasdaq: ... and Drug Administration,has granted marketing approval for Renvela(TM) ... patients with chronic kidney disease on,dialysis. Renvela is ... phosphate binder in the United States. "Since ...
Cached Biology Technology:Volcano Announces Activities at TCT 2007: Expanded Role of IVUS in PCI to be Demonstrated 2Volcano Announces Activities at TCT 2007: Expanded Role of IVUS in PCI to be Demonstrated 3Volcano Announces Activities at TCT 2007: Expanded Role of IVUS in PCI to be Demonstrated 4Agendia BV Announces That its Chief Research Officer Laura van 't Veer has Received a 2007 Breast Cancer Research Foundation Award 2FDA Approves Genzyme's Renvela(TM) for Dialysis Patients 2FDA Approves Genzyme's Renvela(TM) for Dialysis Patients 3FDA Approves Genzyme's Renvela(TM) for Dialysis Patients 4FDA Approves Genzyme's Renvela(TM) for Dialysis Patients 5
(Date:3/24/2015)... , March 24, 2015   NexID Biometrics ... with critical security-authentication needs, today announced the beginning of ... (FFD) solution. The company, based in ... at the three-day Connect:ID Expo, which began here today ... NexID said version 2.0 of its SDK boosts the ...
(Date:3/23/2015)...   HOYOS Labs , a leading global authentication ... the Company will demonstrate multiple biometrics-based technologies under its ... Connect:ID on March 23 through 25, 2015, in ... the IEEE Biometric Open Protocol Standard; free biometrics-based consumer ... control system. BOPS was invented by HOYOS Labs and ...
(Date:3/20/2015)... , Mar. 20, 2015 Research and Markets ... addition of the "India Sensors Market Forecast ... The sensor market is projected to ... Consumer electronics, automotive, industrial and healthcare ... in the country. In addition, adoption of MEMS ...
Breaking Biology News(10 mins):NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3
... at Loyola University Chicago Stritch School of Medicine have ... Institutes of Health to study vitamin D deficiency in ... relation between low vitamin D levels and risks for ... Evidence from numerous previous studies is "inconclusive and needs ...
... WEST LAFAYETTE, Ind. - A Purdue University researcher has ... might lead to improvements in that and other crops. ... landscape architecture, wanted to understand the relationship between natural ... plant architecture, specifically plant height. Schulz said corn could ...
... at the University of North Carolina at Chapel Hill have ... different viruses in an effort to create the ultimate vehicle ... investigators found no side effects from using a "chimeric" virus ... patients with muscular dystrophy. "This trial demonstrates that gene ...
Cached Biology News:Loyola receives NIH grant to study vitamin D deficiency in African populations 2Stronger corn? Take it off steroids, make it all female 2Stronger corn? Take it off steroids, make it all female 3Clinical trial for muscular dystrophy demonstrates safety of customized gene therapy 2
... Agencourt offers pre-validated ... over 1500 amplicons within ... serine/threonin kinases, and more ... These assays were ...
... 384-Well Microarray plates are ideal for use as ... liquid handling applications (down to 5µl). These plates ... well design. Features 384 ... available 70µl well volume (cylindrical well), 55µl ...
Anti-Phospho-JKK/SEK1/MKK4 pAb Description: 100 g rabbit polyclonal antibody. Reacts with human/mouse/rat. Tested in WB. Research Focus: signal transduction Storage: -20C Shipping Tem...
...
Biology Products: